ZONAMPANEL ANHYDROUS

Investigational

Details

Stereochemistry	ACHIRAL
Molecular Formula	C13H9N5O6
Molecular Weight	331.2405
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

OC(=O)CN1C(=O)C(=O)NC2=C1C=C(N3C=CN=C3)C(=C2)[N+]([O-])=O

InChI

InChIKey=SPXYHZRWPRQLNS-UHFFFAOYSA-N

InChI=1S/C13H9N5O6/c19-11(20)5-17-8-4-9(16-2-1-14-6-16)10(18(23)24)3-7(8)15-12(21)13(17)22/h1-4,6H,5H2,(H,15,21)(H,19,20)

HIDE SMILES / InChI

Molecular Formula	C13H9N5O6
Molecular Weight	331.2405
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: https://clinicaltrials.gov/ct2/show/NCT00044057 | https://clinicaltrials.gov/ct2/show/NCT00044070 | Farooqui Akhlaq A., Neurochemical Aspects of Neurotraumatic and Neurodegenerative Diseases, p. 73, retrieved from:https://books.google.ru/books?id=q_G5aon0WbAC&pg=PA73&redir_esc=y#v=onepage&q&f=false

Zonampanel (also known as YM872) was developed as selective, potent and highly water-soluble competitive alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid (AMPA) receptor antagonist. Zonampanel possesses the neuroprotective effect against focal cerebral ischemia and participated in phase II clinical trials in acute stroke patients. However, because of the severe effects, including hallucinations, agitation, and catatonia the further studied were terminated.

Originator

Approval Year

PubMed

Title	Date	PubMed
What lies behind serum urate concentration? Insights from genetic and genomic studies.	2009-12-29	20090896
Characterization of renal tubular apical efflux of zonampanel, an alpha-amino-3-hydroxy-5-methylisoxazole-4-propionate receptor antagonist, in humans.	2008-09	18609448
Role of organic anion transporters in the pharmacokinetics of zonampanel, an alpha-amino-3-hydroxy-5-methylisoxazole-4-propionate receptor antagonist, in rats.	2008-08	18443035
Effect of YM872, a selective and highly water-soluble AMPA receptor antagonist, in the rat kindling and rekindling model of epilepsy.	2006-02-15	16403498
Other neuroprotective therapies on trial in acute stroke.	2006	16651823
Characterization of the renal tubular transport of zonampanel, a novel alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptor antagonist, by human organic anion transporters.	2004-10	15377641
Effect of AMPA receptor antagonist YM872 on cerebral hematoma size and neurological recovery in the intracerebral hemorrhage rat model.	2003-04-25	12706461

Sample Use Guides

In Vivo Use Guide

YM872 (ZONAMPANEL) or placebo will be given as a continuous intravenous (iv) infusion for 24 hours

Route of Administration: Intravenous

Substance Class	Chemical Created by `admin` on `Mon Mar 31 19:12:46 GMT 2025` Edited by `admin` on `Mon Mar 31 19:12:46 GMT 2025`
Record UNII	9X33544ILS
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

ZONAMPANEL ANHYDROUS

Common Name

English

YM 872 ANHYDROUS

Preferred Name

English

1(2H)-QUINOXALINEACETIC ACID, 3,4-DIHYDRO-7-(1H-IMIDAZOL-1-YL)-6-NITRO-2,3-DIOXO-

Common Name

English

YM872 ANHYDROUS

Code

English

YM-872 ANHYDROUS

Code

English

zonampanel [INN]

Common Name

English

Classification Tree Code System Code

NCI_THESAURUS

C47795